Tagged with IQVIA

Europe As China and the US attract an increasing share of commercial clinical trials, Europe is fighting to reclaim its spot as a global research leader. While Europe has world-class hospitals and experienced regulators, it has struggled with a complicated and fragmented approval system that has pushed trial sponsors elsewhere. To…

Global Some of the key projections for the global use of medicines up to 2028, drawn from IQVIA’s report, The Global Use of Medicines 2024: Outlook to 2028. The report states that growth outlook has been raised by 2 percentage points despite lower expectations for COVID-19 vaccines and therapeutics. This increase in…

MEA Peter Lane lays out IQVIA’s nuanced and ambitious vision for healthcare in the vast AMESA region, focused on empowering smarter healthcare and improving patient outcomes. Lane explains how IQVIA hopes to do this through clinical research, maximizing data value, providing technology and analytics to healthcare systems, and ensuring global health…

Portugal While not a major player in clinical trials at the European level, Portugal has untapped potential in this field, leveraging a first pioneering centre in Braga, the country’s strong scientific community, a growing openness to collaboration with industry, and access to a European patient database. Considering the remarkable progress that…

Portugal Mario Martins lays out IQVIA Portugal’s holistic approach to the healthcare sector, covering clinical trials, therapeutic studies, and technology solutions such as compliance CRM and quality control for manufacturing plants. He also foregrounds the importance of both local adaptation and global collaboration in capitalising on the unique challenges and opportunities…

Morocco Senior director and general manager for North, East & West Africa at IQVIA Hocine Mahdi discusses the positive aspects of Morocco’s healthcare landscape and the challenges that remain for multinational companies looking to enter the market, particularly within the context of HTA. Moreover, he outlines the firm’s strategy across African…

Global The global contract research organization (CRO) market is estimated to be worth USD 76.6 billion in 2023 and is projected to reach USD 127.3 billion by 2028, growing at a CAGR of 10.7% from 2023 to 2028. Much of this growth is due to the need for novel clinical trial…

Greece After 15 years of economic struggles coupled with political swings to the left and right, Greece seems to be on its surest footing in decades. Indeed, the Economist observed that the May 2023 election victory of incumbent Greek Prime Minister Kyriakos Mitsotakis (and the heavy defeat handed to his left…

Greece Greece is a middling performer in terms of clinical trial numbers on the European stage, nestled next to Finland and Romania on total trial numbers between 2002 and 2020 but ahead of Germany and Italy on trials per capita. However, the pharmaceutical industry does see opportunities for establishing greater trial…

Greece Since 2020, IQVIA has established health economics, technology, and market research hubs in Greece, leveraging the country’s talent pool to serve a range of EMEA markets. Nikos Kostaras outlines what else Greece has to offer to IQVIA, as well as the key services that the firm brings to its Greek…

Middle East & Africa Within the context of the MEA region’s maturing regulatory environment, the expansion of healthcare coverage and regulatory changes aimed at making the New Molecular Entities (NMEs) review process more efficient, registrations have increased in Saudi Arabia, UAE, Tunisia and Egypt, but slowed down in other territories. Results from the second…

Global Driven by increased demand from Big Pharma, mid-caps, and biotechs for outsourcing services, the USD 70 billion global contract research organisation (CRO) market is predicted to grow at a CAGR of between 11 and 12 percent over the next five to seven years, with differing estimates placing its total size…